Cargando…
Efficacy and Safety of Zhenyuan Capsule for Coronary Heart Disease with Abnormal Glucose and Lipid Metabolism: Study Protocol for a Randomized, Double-Blind, Parallel-Controlled, Multicenter Clinical Trial
BACKGROUND: Coronary heart disease (CHD) and abnormal glucose and lipid metabolism are closely associated and generally coexist. The Qi and Yin deficiency syndrome is a common disease pattern encountered in traditional Chinese medicine. We designed a protocol to determine the effectiveness and safet...
Autores principales: | Qiao, Yu, Zhang, Jingchun, Liu, Yue, Liang, Zhiqi, Wang, Yuhua, Zheng, Wei, Shi, Dazhuo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944192/ https://www.ncbi.nlm.nih.gov/pubmed/29853944 http://dx.doi.org/10.1155/2018/1716430 |
Ejemplares similares
-
Efficacy and safety of Zhenyuan capsule in the treatment of chronic heart failure: A meta-analysis and trial sequential analysis
por: Zhang, Zengyu, et al.
Publicado: (2023) -
Carotid artery plaque intervention with Tongxinluo capsule (CAPITAL): A multicenter randomized double-blind parallel-group placebo-controlled study
por: Zhang, Mei, et al.
Publicado: (2019) -
A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Study of the Effects of Tongxinluo Capsules in Acute Coronary Syndrome Patients with High On-Treatment Platelet Reactivity
por: Zhang, Lei, et al.
Publicado: (2018) -
Zhizhu Kuanzhong Capsule in treating patients with functional dyspepsia postprandial distress syndrome: study protocol for a multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial
por: Xiao, Mengli, et al.
Publicado: (2022) -
Icenticaftor, a CFTR Potentiator, in COPD: A Multicenter, Parallel-Group, Double-Blind Clinical Trial
por: Martinez, Fernando J., et al.
Publicado: (2023)